Diabeloop
- hard tech
- biotechnology
- horizon europe
- sustainable development goals
- core ai
- tech for business
- spinout
- ai applications
- eit ecosystem
- observatoire deeptech
- diabetes
- eit health
- tech for patients
- personal health
- biotech, medtech and e-health
- digital care
- eit kic partners
- remote monitoring
- headstart (eit health)
- digital therapeutics
- metabolism
- headstart 2016 (eit health)
- innovation projects (eit health)
- innovation projects 2019 (eit health)
- innovation projects 2018 (eit health)
Financials
Estimates*
EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2023 |
---|---|---|---|---|---|---|---|
Revenues | - | - | - | <1m | <1m | <1m | <1m |
% growth | - | - | - | - | 332 % | 45 % | - |
EBITDA | (<1m) | (<1m) | (1.5m) | (1.9m) | (3.7m) | - | - |
% EBITDA margin | - | - | - | (3589 %) | (1596 %) | - | - |
Profit | <1m | <1m | (<1m) | (1.1m) | (1.8m) | - | - |
% profit margin | - | - | - | (2027 %) | (788 %) | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Spinout | ||
€50.0k | Grant | ||
* | €13.5m | Early VC | |
€950k | Grant | ||
€2.0m | Grant | ||
€50.0k | Grant | ||
N/A | $3.2m | Grant | |
$34.3m | Series B | ||
€43.5k | Grant | ||
* | €70.0m | Series C | |
N/A | Debt | ||
* | N/A | €15.0m Valuation: €350m | Late VC |
Total Funding | €136m |
Related Content
Recent News about Diabeloop
EditDiabeloop is a health-tech startup that operates in the medical device industry, specifically focusing on diabetes management. The company has developed a self-learning algorithm that uses therapeutic artificial intelligence (AI) to automate the treatment of Type 1 diabetes. This means that the system learns from the patient's behavior and adjusts the treatment accordingly, reducing the need for constant decision-making by the patient.
The company's primary market is individuals living with Type 1 or Type 2 diabetes, and their families. Diabeloop's business model is centered around the development and sale of its AI-powered medical device. The device is currently marketed in France and several other European countries, and the company has signed development agreements with international partners such as Roche Diabetes Care, ViCentra, SOOIL, Terumo Corporation, and BIOCORP.
Diabeloop's revenue is generated through the sale of its medical device to patients and healthcare providers. The company has recently completed its third round of financing, raising a total of 70 million euros to support its international expansion and research and development activities.
In simple terms, Diabeloop is a company that uses AI to help people with diabetes manage their condition more easily and effectively. It sells its product in Europe and is looking to expand internationally.
Keywords: Diabetes Management, Artificial Intelligence, Medical Device, Type 1 Diabetes, Type 2 Diabetes, Health-Tech Startup, Therapeutic AI, International Expansion, Research and Development, Patient-Centric Approach.